Dosing and Safety Recommendations for Tenofovir Alafenamide (Vemlidy) in Chronic Hepatitis B

Renal Impairment Dosing

For adults and adolescents (≥12 years) with an estimated glomerular filtration rate ≥ 15 mL/min, no dose adjustment of tenofovir alafenamide (TAF) is required, providing a practical advantage over tenofovir disoproxil fumarate (TDF). American Association for the Study of Liver Diseases (AASLD) 2018 guidance supports this recommendation. 1
The 2022 Korean Association for the Study of the Liver (KASL) guideline specifically recommends TAF over TDF for treatment‑naïve patients who have, or are at risk for, renal dysfunction. 1

Patients with compensated cirrhosis (Child‑Pugh A) can be safely treated with TAF, while use in decompensated cirrhosis (Child‑Pugh B/C) remains off‑label pending regulatory approval. European Association for the Study of the Liver (EASL) 2025 guidance notes the availability of emerging data for the latter group. 5

Prior to initiating TAF, AASLD 2018 recommends baseline assessment of renal function—including serum creatinine, serum phosphorus, creatinine clearance, urine glucose, and urine protein—and repeat monitoring at clinically appropriate intervals throughout therapy. [2][3]

AASLD 2018 lists TAF together with entecavir and TDF as first‑line oral antiviral agents for chronic hepatitis B. [2][6]3
In HBeAg‑negative patients, TAF achieves virologic suppression comparable to TDF (≈ 90 % vs ≈ 93 % HBV DNA suppression at 2 years) while offering superior renal and bone safety profiles. Evidence derives from AASLD‑endorsed clinical studies. [2][7]

EASL 2025 emphasizes that renal function is a key determinant when choosing among nucleos(t)ide analogues for chronic hepatitis B, favoring agents with a more favorable renal safety profile such as TAF. 5